drugset / Trial / NCT02078609

A Safety and Efficacy Study of LGH447 in Patients With Acute Myeloid Leukemia (AML) or High Risk Myelodysplastic Syndrome (MDS)

NCT02078609

Phase 1 Completed 70 enrolled Novartis Pharmaceuticals
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This study will assess the safety and preliminary efficacy of escalating doses of LGH447 monotherapy in AML and MDS and LGH447 in combination with midostaurin in AML.

Timeline

Start
2014-03-20
Primary completion
2019-04-18
Completion
2019-04-18

Drugs

EvaluationDrugModalityDoseRoute
Subject LGH447 Small molecule Oral
Background Midostaurin Small molecule